CareDx

CareDx has three revenue lines: testing services, which include post-transplant rejection surveillance via its AlloSure and AlloMap blood tests; a digital-health software suite that organ-transplant centers license for patient management and analytics; and a specialty transplant pharmacy that fills physician prescriptions directly for organ recipients. Each of these lines is recurring in nature, linked to a single transplant event.

CareDx’s core commercial focus is kidney and heart transplantation. Its HLA-typing products, which are used pre-transplant to match donors and recipients, support broader solid-organ applications, but the firm’s most mature clinical evidence and market penetration sit within renal and cardiac transplant programs.

CareDx is a medical-technology company, not an investment firm, so it does not maintain a family-office investment committee or asset-allocation function. Strategic capital allocation, including M&A, is governed by the Board of Directors and senior management team under standard public-company fiduciary duties. The current CEO guides corporate strategy, but the firm does not publicly disclose a dedicated chief investment officer or a family-wealth governance structure.